{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:03:58Z","timestamp":1784347438082,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106747","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:04:39Z","timestamp":1757660679000},"page":"106747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Post marketing real-world experience of ravulizumab in NMOSD"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7530-6800","authenticated-orcid":false,"given":"Anu","family":"Jacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7890-9757","authenticated-orcid":false,"given":"Azza","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami R","family":"Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A","family":"Deif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzi","family":"Elhabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luai","family":"Eldweik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Mifsud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Shatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106747_bib0009","unstructured":"Canadian Agency for Drugs and Technologies in Health. Pharmacoeconomic report: eculizumab (soliris): Alexion Pharma Canada Corp. 2020."},{"key":"10.1016\/j.msard.2025.106747_bib0008","unstructured":"Canadian Agency for Drugs and Technologies in Health. Ravulizumab (ultomiris): CADTH reimbursement reviews and recommendations. 2022."},{"key":"10.1016\/j.msard.2025.106747_bib0016","unstructured":"CDC. Advisory committee on immunization practices (ACIP). 2024."},{"issue":"5","key":"10.1016\/j.msard.2025.106747_bib0011","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.msard.2025.106747_bib0023","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.kint.2023.12.021","article-title":"A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome\/complement-mediated thrombotic microangiopathy","volume":"105","author":"Che","year":"2024","journal-title":"Kidney Int."},{"issue":"10206","key":"10.1016\/j.msard.2025.106747_bib0006","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106747_bib0018","article-title":"A global, long-term, prospective, observational registry of patients with anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) treated with complement component 5 inhibitor therapies (C5ITs) eculizumab or ravulizumab","volume":"103","author":"Fam","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2025.106747_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2025-001286","article-title":"Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report","volume":"7","author":"Jacob","year":"2025","journal-title":"BMJ Neurol. Open"},{"issue":"11","key":"10.1016\/j.msard.2025.106747_bib0022","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9451","key":"10.1016\/j.msard.2025.106747_bib25","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.msard.2025.106747_bib0013","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12185-016-1946-x","article-title":"Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review","volume":"103","author":"Miyasaka","year":"2016","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.msard.2025.106747_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231181177","article-title":"Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan","volume":"16","author":"Nakashima","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106747_bib0017","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208776","article-title":"NMO SPOTLIGHT registry: real-world clinical outcomes with eculizumab and ravulizumab in anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) (P11-8.013)","volume":"104","author":"Obeidat","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106747_bib0021","first-page":"15","article-title":"Case report: transition from anti-CD20 therapy to inebilizumab for 14 cases of neuromyelitis optica spectrum disorder","author":"Osborne","year":"2024","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106747_bib0007","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106747_bib0003","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2025.106747_bib0004","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106747_bib0012","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40620-018-0517-z","article-title":"Eculizumab in pregnancy: a narrative overview","volume":"32","author":"Sarno","year":"2019","journal-title":"J. Nephrol."},{"issue":"12","key":"10.1016\/j.msard.2025.106747_bib0024","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/ndt\/gfw314","article-title":"Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab","volume":"31","author":"Servais","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.msard.2025.106747_bib0005","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106747_bib0015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106747_bib0010","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.msard.2025.106747_bib0001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2025.106747_bib0020","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s40120-024-00640-7","article-title":"Safety and effectiveness of Satralizumab in Japanese patients with neuromyelitis optica spectrum disorder: a 6-month interim analysis of post-marketing surveillance","volume":"13","author":"Yamamura","year":"2024","journal-title":"Neurol. Ther."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:27:00Z","timestamp":1784345220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"alternative-id":["S2211034825004894"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106747","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post marketing real-world experience of ravulizumab in NMOSD","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106747"}}